Dominik Feuerbach

This inventor holds 23 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Nicotinic Acetylcholine Receptor. Top assignee: Novartis Ag. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dominik Feuerbach. Retrieved from https://idiyas.com/inventor/dominik-feuerbach

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 8)

% Patents Active = 73.9

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 4.8

ph-index = 7

Forward Citations = 84(Granted Patents)

Location History:

Mullheim, DE (2009 - 2017)
Müllheim, DE (2011 - 2022)
Basel, CH (2017 - 2022)

Company Filing History:

23 out of 3,975

Novartis Ag

patents

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

TREM2 Antibodies

Nicotinic Acetylcholine Receptor

Alpha 7 Agonists

Biomarkers

CNS Diseases

Cholinergic Ligands

Psychotic Disorders

Neurodegenerative Disorders

Aza-Bicycloalkyl Ethers

Organic Compounds

Quinuclidines

Aza-Bicycloalkyl Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595305 - TREM2 STABILIZING ANTIBODIES (2026-04-07),

2. 11492402 - TREM2 stabilizing antibodies (2022-11-08),

3. 11359241 - Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment (2022-06-14),

4. 11311525 - Use of alpha 7 nicotinic acetylcholine receptor agonists (2022-04-26),

5. 11096916 - Use of nicotinic acetylcholine receptor alpha 7 activators (2021-08-24),

6. 10537539 - Use of nicotinic acetylcholine receptor alpha 7 activators (2020-01-21),

7. 9849117 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists (2017-12-26),

8. 9828642 - Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment (2017-11-28),

9. 9657010 - Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators (2017-05-23),

10. 9567343 - Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists (2017-02-14),

11. 9475811 - 1-aza-bicyclo[3.3.1]nonanes (2016-10-25),

12. 9206181 - 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders (2015-12-08),

13. 9012451 - Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists (2015-04-21),

14. 8933090 - 1-aza-bicyclo[3.3.1]nonanes (2015-01-13),

15. 8759346 - Organic compounds (2014-06-24),

Title: The Innovative Mind of Dominik Feuerbach

Introduction:

Dominik Feuerbach, a talented inventor hailing from Müllheim, Germany, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

Dominik Feuerbach's latest patents include cutting-edge advancements in renewable energy technologies, smart home devices, and sustainable transportation solutions.

Career Highlights:

Throughout his illustrious career, Dominik Feuerbach has consistently pushed the boundaries of innovation, with a focus on creating solutions that improve the quality of life for people around the world. His work has been recognized for its creativity and impact on various industries.

Collaborations:

Dominik Feuerbach has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has led to the successful development of several groundbreaking technologies.

Conclusion:

In conclusion, Dominik Feuerbach stands as a visionary inventor whose passion for innovation continues to drive him towards creating a brighter and more sustainable future for all. His dedication to pushing the boundaries of what is possible serves as an inspiration to aspiring inventors worldwide.

Profile summary based on public USPTO records.